Objective: In this study, we investigated the detailed clinical findings and underlying genetic defect in 3 presumably related Bulgarian families displaying dominantly transmitted adult onset distal myopathy with upper limb predominance.
Until recently, 3 filamin C (FLNC) mutations (p.Trp2710X, p.Val930_Thr933del, and p.Lys899_Val904delinsValCys) [11] [12] [13] [14] were known to cause adult-onset MFM with a variable but commonly limb-girdle pattern of muscle weakness. Filamin C is a musclespecific actin cross-linking protein involved in cytoskeleton organization and signaling. 15 Functional and structural modeling suggests that mutant FLNC recruits FLNC-associated proteins, forming aggregates that gradually destabilize muscle tissue homeostasis. 14, 16 Recently, 2 novel missense FLNC mutations (p.Met251Thr, p.Ala193Thr) were associated with a peculiar distal myopathy phenotype with hand muscle involvement and lack of pathologic protein aggregation. 17 These N-terminally located mutations were found to increase actin-binding affinity of FLNC. 17 We report on 3 distantly related families with dominantly inherited distal myopathy with upper limb predominance caused by a novel loss-of-function FLNC mutation.
METHODS Patients and evaluation. Thirteen patients (6 men, 7 women) from 3 pedigrees (2701, 2702, 2703) originating from the same village underwent detailed neurologic examination (performed by V.G., T.C., V.M., I.T.). Thirteen at-risk, asymptomatic relatives aged 17-87 years were also evaluated.
Standard nerve conduction studies (NCS) and concentric needle EMG were performed (by V.G.) using a DantecKeypoint portable electromyograph (Natus, Copenhagen, Denmark). Routine EKG and transthoracic cardiac ultrasound were performed (by M.G.).
Standard protocol approvals, registrations, and patient consents. Written informed consent was obtained from all participants. This study was approved by institutional review boards of the Medical University-Sofia and the University of Antwerp.
MRI. Patient 2701:IV-3 underwent MRI of lower and upper
limbs and trunk muscles with a 1.5-T MRI unit with a 4-channel phased array body coil (Siemens Essenza, Erlangen, Germany). Images obtained were T1-weighted (T1W/SE, repetition time [TR] ϭ 545, echo time [TE] ϭ 9.7), T2-weighted nonfat-saturated spin echo (T2W/FSE, TR ϭ 5,202/3,700, TE ϭ 96), and turbo inversion recovery magnitude with fat saturation (T2 TIRM, TR ϭ 4,020, TE ϭ 57/82, inversion time ϭ 170). Cross-sections from pelvic girdle, thighs, and lower leg muscles were made with 7.5 mm slice thickness.
Histologic analysis and electron microscopy. Open muscle biopsies were obtained from the medial head of the right gastrocnemius muscle in patients 2701:IV-3 and 2701:IV-4, and of the tibialis anterior muscle in patient 2702:IV-1. The latter sample was analyzed using standard histologic and immunohistochemical light microscopy (LM) techniques. 18 Antibodies used were against dystrophin (Dys1/2/3), dystroglycans (␣/␤), sarcoglycans (␣/␤/␥/␦), dysferlin (Ham1/Ham2), caveolin, spectrin, utrophin, merosin (80 kDa/200 kDa), 4H8 -2-laminin ␣-2 chain, emerin, lamin A/C, laminin, vimentin, collagen VI, collagen IV, ␣-actinin, actin, desmin, myosin, MHC-developmental, titin, tropomyosin, telethonin, and vinculin (details available upon request). Further stainings were performed using ␣B-crystallin (1:2,000, NovoCastra, Wetzlar, Germany), myotilin (1:1,000, NovoCastra), and FLNC (RR90 19 1:1,000). The peroxidase-antiperoxidase technique was used for polyclonal antibodies and the avidin-biotin complex technique for monoclonal antibodies.
The biopsy samples of patients 2701:IV-3 and 2702:IV-1 were investigated using standard electron microscopy (EM). Semithin resin sections were stained with toluidine blue. Ultrathin sections were examined using a FEI CM10 transmission electron microscope (Philips, Amsterdam, the Netherlands) at 60 kV.
The biopsy from patient 2701:IV.4 was suitable only for Western blotting.
Linkage studies. Genome-wide linkage analysis was performed using an in-house developed panel of 360 STR markers. Additional polymorphic markers were selected for fine-mapping (http://www.ncbi.nlm.nih.gov/unists/). Linkage was calculated using MLINK 20 under an autosomal dominant model, equal male/female recombination rates, and a 0.0001 disease frequency. Asymptomatic individuals were classified as unaffected. Due to late disease onset, 6 penetrance classes were assigned: 0 -20 years/0.6%, 21-35 years/9%, 36 -45 years/37%, 46 -55 years/74%, 56 -65 years/94%, and 66 -80 years/99%. Mutation analysis. Genomic DNA was extracted from peripheral blood using standard procedures. All 48 exons, exonintron boundaries, and 5ЈUTR of FLNC were amplified using primers designed with Primer3 v0.4.0 21 ( figure 1A ). Muscle weakness remained restricted to distal limbs in 11/13 patients. Distal extensors were typically more severely affected than flexor muscles. Atrophy was seen mostly in interosseus muscles (especially the first dorsal), thenar, and anterior tibial muscles. Asymmetry was noted in 4/13 patients. All but one patient remain ambulatory to date. Distal deep tendon reflexes were reduced or absent. Distal sensory abnormalities were observed in 6 patients. Five mutation carriers (2701:IV-16, 2701:IV-14, 2702:IV-3, 2701:V-1, 2701:V-2) between 32 and 59 years of age were clinically normal.
Cardiac studies were performed on 7 patients (table 1). Only patient 2702:IV-1 showed cardiomyopathy on cardiac ultrasound with mild systolic dysfunction of the left ventricle, 50% ejection fraction, and mild global hypokinesis. There were no data for coronary heart disease.
Serum creatine kinase (CK) levels in 6 patients and 2 asymptomatic carriers ranged from normal to 6-fold elevated.
NCS in 8 symptomatic individuals revealed diminished compound muscle action potential (CMAP) amplitudes in median, peroneal, and tibial nerve recordings. Motor nerve conduction velocity remained mostly normal. Sensory nerve action potentials were normal except in patients 2702:III-1 and 2701:IV-10. EMG in 6 patients revealed a myogenic pattern in 5 patients, and mixed myogenic and neurogenic in the anterior tibial muscle of patient 2702:III-1. Spontaneous activity (positive sharp waves) was recorded from one anterior tibial muscle (2701:IV-3).
MRI studies. MRI study (figure 1B) of patient 2701: IV-3 disclosed a marked increase in signal intensity in triceps surae muscles bilaterally in both T1 and T2/TSE, consistent with fat replacement and lack of hyperintensity on TIRM sequences, indicating absence of muscular edema. Muscle volume was generally preserved. Tibialis anterior muscle was involved bilaterally, more pronounced on the left, as well as the medial head of gastrocnemius and soleus muscles, with fat replacement increasing from knees to ankles. Minor changes were seen in the distal part of peroneus longus and in the periphery of extensor digitorum longus. The posterior tibial muscle was preserved. In the proximal aspect of the lower limbs, the hamstrings and the gluteus maximus were affected, with sparing of the quadriceps, semitendinosus, gracilis, and sartorius. The shoulder girdle and upper arm muscles appeared normal.
Histologic features. Biopsy 2702:IV-1 showed variations in muscle fiber size on LM (figure 2). Fiber splitting, pyknotic nuclear clumps, a single necrotic fiber, and one fiber with a rimmed vacuole were also present. Endomysial fibrosis and a small group of lobulated fibers close to a tendon were observed. Centralized nuclei were seen in 3% of the muscle fibers. No abnormal deposits, vacuoles, or hyaline inclusions were observed in the sarcoplasm. Oxidative enzymes staining showed focal areas of decreased activity. Myofibrillar ATPase, after preincubation at different pHs, showed a type 1 fiber predominance. Immunohistochemistry showed normal sarcolemmal proteins. There were no deposits of desmin, ␣-actinin, actin, titin, or tropomyosin. In the sarcoplasm, limited amounts of irregular ␣B-crystallin granulo-filamentous material were seen and very few fine granular deposits of myotilin. Apart from a single fiber containing FLNCimmunoreactive rods, no other FLNC-immunoreactive deposits were detected.
The ␣B-crystallin and FLNC deposits did not colocalize with any of the other immunostained proteins. The corresponding fibers looked normal on trichrome and hematoxylin & eosin staining.
Ring-like fibers were observed upon toluidine blue staining of semithin resin sections, although similar changes could not be detected on NADH-TR staining. Toluidine-stained sections of a second biopsy (patient 2701:IV-3) showed slight fiber size 
On the ultrastructural level, the 2702:IV-1 biopsy showed a wide spectrum of ultrastructural changes, including myofibrillar disorganization (figure 2J and inset) with diverse Z-disc abnormalities, such as streaming, densified striped material, small rods (insets of figure 2, J and K), and dappled bodies. Both preserved and disorganized ring-like muscle fibers were present, along with lobulated-like fibers with myofibrillar disorganization and fine granular sarcoplasmic masses (arrows, figure 2K ).
There were neither deposits of electron-dense granular material nor accumulation of intermediate filaments. No rimmed vacuoles and no sarcoplasmic or intranuclear tubulofilamentous inclusions nor cytoplasmic bodies or spheroids were present. The ultrastructural changes observed in patient 2701:IV-3 were milder and included rare focal myofibrillar disorganization and Z-disc abnormalities, with streaming and flag-like semidense extensions, in addition to rare fibrillogranularlike aggregates (data not shown).
Linkage analysis. Genome-wide scan and 2-point linkage analysis using penetrance classes showed linkage to chromosome 7q21.1-q35 in family 2701 (table e-2). The common geographic origin and phenotype among the families suggested a common pathogenic mutation. Genotype analysis revealed a common haplotype shared by all patients in the 3 families, consistent with a founder effect (figure e-1). The pedigrees were therefore combined in the consecutive fine-mapping analysis, yielding a cumulative lod score of Z max ϭ 3.54 at ϭ 0 at D7S635. Key recombinants (2701:IV-4, 2702:IV-1, and 2703:III-2) delineated the disease haplotype to a 9.76-Mb region between markers D7S650 and D7S649. All clinically affected patients and 5 asymptomatic individuals (2701:IV-14, 2701:IV-16, 2702:IV-3, 2701:V-1, 2701:V-2) carried the disease haplotype.
Mutation analysis. The candidate region contained 113 genes, of which only FLNC is predominantly expressed in striated muscles and is already associated with hereditary myopathy. Mutation screening of FLNC revealed an unknown c.5160delC variation in exon 30 of all disease haplotype carriers (figure 3 and figure e-1) resulting in a frameshift and a premature stop codon (p.Phe1720LeufsX63). The variation was absent from 177 Caucasian and 87 Bulgarian controls.
FLNC expression studies.
We studied the functional effect of the c.5160delC mutation at the transcriptional level in muscle tissue of patients 2701:IV-4 and 2702:IV-1. Quantitative RT-PCR revealed a de- crease of ϳ50% in FLNC mRNA (normalized against HMBS) in the patients relative to 2 unrelated controls (figure e-2A). Direct sequencing and length-dependent separation showed that the FLNC cDNA of patients consisted exclusively of wild-type transcript (figure 3, e-2B). Although FLNC is predominantly expressed in striated muscle, 24 we demonstrated FLNC transcript in lymphoblasts, thus providing an additional tool for expression studies. The FLNC mRNA reduction was rescued by cycloheximide treatment of lymphoblast cultures from patients 2701:IV-3 and 2702: IV-1 (figure e-2C), with a selective increase in c.5160delC mutant RNA (figure e-2D ). This suggests that the FLNC mRNA decrease in our patients is due to NMD 22 of the c.5160delC transcript. Total protein extracts from muscle biopsies of patients 2701:IV-3, 2701:IV-4, 2702:IV-1, and 4 agematched controls were immunoblotted with antibodies directed against epitopes located in the first 2 Ig-like domains (RR90 19 ) and in the utmost C-terminal part (Abnova Corporation) of the FLNC protein. Consistent with the diminished RNA levels, densitometric quantification of the FLNC protein signal intensity revealed a reduction of ϳ50% in FLNC expression in patient muscle tissue, as compared to controls (figure e-2, E and F). No shorter protein fragments were detected, even when loading excessive protein amounts and exposing the membrane for longer times (figure e-2F). DISCUSSION We report on 3 distantly related Bulgarian families with distal myopathy due to a novel truncating FLNC mutation.
Three known FLNC mutations [11] [12] [13] [14] cause adult onset limb-girdle muscle weakness mainly affecting lower limbs, with some foot dorsiflexor and upper limb weakness upon disease progression. CK levels varied from normal to tenfold elevated. Some patients had cardiac or respiratory involvement. 14 Recently, a distal myopathy phenotype was described in 2 families with FLNC missense mutations. 17 Disease started in the third decade of life with thenar muscle weakness, followed by posterior calf muscle involvement and slow progression to proximal involvement. None of the affected individuals had respiratory insufficiency; CK levels were normal to twofold increased and 2 patients displayed cardiomyopathy. The c.5160delC mutation reported in our study causes adult-onset distal myopathy often characterized by upper limb predominance. Thenar muscles are consistently involved but finger extensors and foot dorsiflexors are the most severely affected. Onset age is slightly later and progression is milder than reported earlier, 17 with proximal weakness occurring only rarely. None of the subjects displayed respiratory insufficiency. Cardiomyopathy was documented in one patient.
In our patients, NCS typically revealed diminished CMAP amplitudes corresponding to recordings from atrophied distal muscles and myogenic changes on needle EMG. Clinical sensory loss was noted in 6/13 patients. Three of these underwent NCS, revealing abnormal sensory parameters and mixed myogenic/neurogenic pattern on needle EMG in 1 (2702:III-1), possibly suggesting a small fiber neuropathy in the other 2. Although we have no strong arguments for a concomitant peripheral neuropathy in our families, it was previously suspected in patients carrying the FLNC p.Trp2710X mutation.
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In patients with limb-girdle filaminopathy, muscle pathology revealed typical MFM hallmarks (e.g., myofibril disorganization and large protein aggregates). [12] [13] [14] In contrast, the recently reported distal myopathy patients showed unspecific myopathologic abnormalities and consistent lack of myofibrillar aggregation on LM. 17 We studied 2 biopsies from a severely affected tibialis anterior muscle (2702:IV-1) and a clinically preserved, but radiologically affected gastrocnemius muscle (2701:IV-3). Analogous to the previous study, 17 LM analysis revealed mild myopathic changes and a lack of myofibrillar aggregation. Very rare ␣B-crystallin and FLNC-positive inclusions were noted, but they did not resemble typical MFM morphology. EM analysis, however, demonstrated various ultrastructural changes, including myofibrillar disorganizations with diverse Z-disc abnormalities. Although based on a limited sample, our morphologic data suggest subtle myofibrillar changes in this particular form of filaminopathy. These minor changes may be compatible with those observed in MFM, although results of routine LM and immunohistochemistry are certainly not typical of this diagnosis.
Functional studies of the p.Trp2710X FLNC mutation showed that, although mutant proteins are expressed, they interact abnormally and recruit other cytoskeletal and sarcomeric proteins in large aggregates that ultimately disturb sarcomeric structure. 16 This MFM pathology is consistent with a gain-oftoxic-function disease mechanism.
The 2 known distal myopathy FLNC mutations are N-terminally located amino acid substitutions that increase the actin-binding activity of the mutant protein. However, the precise pathomechanism is still unclear. 17 Our results broaden the genetic spectrum of filaminopathies by demonstrating the first FLNC frameshift mutation. The truncating c.5160delC mutation triggers NMD, thus decreasing total FLNC mRNA to ϳ50% of normal in patients' muscle tissue and lymphocytes and halving the FLNC protein level in muscle tissue. These results are compatible with a loss-of-function mechanism leading to FLNC haploinsufficiency. Because FLNC is highly required in muscles for cross-linking actin with Z-disc proteins and the sarcolemma, it may be dosage sensitive. Alternatively, stoichiometric changes may influence FLNC's signaling functions. 24, 25 Haploinsufficiency has never been reported in patients carrying a FLNC mutation. A recent study reports a loss-of-function mouse model using a partially deleted FLNC gene, making it relevant for our c.5160delC-associated phenotype. 26 Although mice homozygous for the truncated allele are not viable, heterozygous mice display no obvious myopathy phenotype. 26 Like humans, the mice might display a milder phenotype that emerges only at older age. However, detailed phenotyping of heterozygous animals is currently lacking.
Our combined findings suggest that the unusual clinical presentation and absence of classic MFM morphology in our families is associated with a null allele causing FLNC haploinsufficiency. Further functional studies are required to define whether the distal myopathy phenotype in the presented patients and in 2 recently reported families 17 is caused by 2 independent molecular pathways, or whether the 3 mutations have a common downstream effect on functionality of muscle cells despite different triggering events.
Our study enlarges the clinical spectrum of filaminopathies and extends the histopathologic and genetic heterogeneity of hereditary distal myopathies. Our findings stress the importance of EM for detecting myofibrillar abnormalities in patients suspected of a distal or myofibrillar myopathy, particularly in the absence of typical MFM features on LM. FLNC haploinsufficiency may cause subtle myofibrillar changes that risk going undetected on LM. Further morphologic studies in additional families could provide more insight into this matter.
For genetic counseling in distal myopathy families it is essential to consider the late disease onset and possible reduced penetrance of FLNC mutations.
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